Last reviewed · How we verify
Fondaparinux Sodium (Arixtra)
Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation.
Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation. Used for Acute deep vein thrombosis (DVT) treatment, Acute pulmonary embolism (PE) treatment, Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery.
At a glance
| Generic name | Fondaparinux Sodium (Arixtra) |
|---|---|
| Also known as | Arixtra |
| Sponsor | Paul Di Cesare,MD |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III, enhancing its ability to inactivate Factor Xa. By blocking Factor Xa, it interrupts the intrinsic and common pathways of the coagulation cascade, preventing the conversion of prothrombin to thrombin and thus inhibiting clot formation. Unlike heparin, fondaparinux does not inhibit thrombin directly.
Approved indications
- Acute deep vein thrombosis (DVT) treatment
- Acute pulmonary embolism (PE) treatment
- Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery
Common side effects
- Bleeding
- Thrombocytopenia
- Anemia
- Injection site hematoma
- Nausea
- Elevated liver enzymes
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction (PHASE4)
- Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) (PHASE3)
- Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care (PHASE3)
- Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
- Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fondaparinux Sodium (Arixtra) CI brief — competitive landscape report
- Fondaparinux Sodium (Arixtra) updates RSS · CI watch RSS
- Paul Di Cesare,MD portfolio CI